lacritin
Recombinant proteinexperimental
Lacritin is a 12.3 kDa glycoprotein encoded in humans by the LACRT gene. Lacritin's discovery emerged from a screen for factors that stimulate tear protein secretion. Lacritin is a secreted protein found in tears and saliva. Lacritin also promotes tear secretion, the proliferation and survival of epithelial cells, and corneal wound healing Lacritin is thus a multifunctional prosecretory mitogen with cell survival activity. Natural or bacterial cleavage of lacritin releases a C-terminal fragment that is bactericidal. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2017 (NCT03226444)
Timeline
Indications
Mechanism of action
- Syndecan-1ACTIVATOR
SDC1 activator
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLacritin ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06854393 | Phase 2 | May 23, 2025 | Henry M. Jackson Foundation for the Advancement of Military Medicine, TearSolutions, Inc., United States Army |
| NCT03226444 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2017 | TearSolutions, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TearSolutions, Inc. | For profit | 2 | 1 | 1 | 2017 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 1 | 1 | 2025 |
| United States Army | Government | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1